Dr. Swati Garg

About

Dr. Swati Gargs scientific expertise spans molecular parasitology, host–pathogen interactions, and drug discovery, with a primary focus on malaria and other neglected tropical diseases. Her research explores host-directed therapeutic strategies, parasite invasion mechanisms, and molecular targets for antimalarial intervention. She has contributed extensively to understanding the molecular basis of Plasmodium infection and resistance, leading to publications in reputed international journals. Integrating molecular biology, immunology, and translational research, Dr. Gargs studies aim to develop innovative therapeutic and diagnostic approaches to combat parasitic diseases effectively.

Experience

• >10 years

Qualification

• PhD

Award & Recognition

• Gandhian Young Technological Innovation (GYTI) Award, BIRAC–SRISTI (2019) - for developing engineered E. coli for high-throughput drug screening against malaria and kala-azar.
• Young researcher award 1st National Biomedical Research Competition (NBRCom) organized by the Society for Young Biomedical Scientists (SYBS) (2018).
• DST-INSPIRE Faculty Award (2014) - for independent research in Leishmania donovani Biology.
• EMBO Travel Award (2015) - to attend The EMBO Meeting.
• Carl Storm International Diversity Fellowship (2013) - for attending the Gordon Research Conference on Malaria.

Research

Total: 35+ total publications, h-index: 12, Citations: 642, i10-index: 18

• Garg S. et al. (2013). Calcium-dependent permeabilization of erythrocytes by a perforin-like protein during egress of malaria parasites. Nature Communications, 4, 1736. (IF: 16.6)
• Sah R.K.#, Garg S.# et al. (2019). Phosphatidic acid homeostasis regulated by phosphatidic acid phosphatase as a druggable target in malaria. Cell Death Discovery, 5, 107. (IF: 7.0)
• Chaurasiya A.#, Garg S.# et al. (2020). Subversion of host NAD⁺ metabolism regulates pathogen growth. Cell Death Discovery, 7, 10. (IF: 7.0)
• Ramu D.#, Garg S.# et al. (2017). Novel β-carboline–quinazolinone hybrids disrupt Leishmania redox homeostasis. Biochemical Pharmacology, 129, 26–42. (IF: 5.8)
• Joshi P.#, Garg S.# et al. (2024). Targeting host inducible-HSP70 with PES-Cl as an antiviral strategy against SARS-CoV-2. International Journal of Biological Macromolecules. (IF: 8.2)

Patent

• Antimalarial Composition Comprising Arjunetin and Artemisinin
• Inventors: S.N. Gummadi, A. Senthilkumar, S. Singh, S. Garg
• Application No: 202441091954 (Filed: 26 Nov 2024, Indian Patent)

Certifications

• AICTE Recognized Faculty Development Programme on “Industry-Academic Linkages in Higher Educational Institutes”.

Area of Interest

• Molecular mechanisms of malaria and leishmaniasis pathogenesis
• Host-directed therapeutics and drug repurposing
• Host-pathogen interactions
• Signaling mechanisms of parasite infection